Management & Consultants
Michael K. Korenko, Sc.D.
President • CEO Vivos, Inc.
Mike Korenko has a Doctor of Science from MIT, was a NATO Postdoctoral Fellow at Oxford University, and was selected as a White House Fellow for the Department of Defence.
He currently is the author of 28 patents and has received many awards, including the National Energy Resources Organization Research and Development Award, the U.S. Steelworkers Award
for Excellence in Promoting Safety, and the Westinghouse Total Quality Award for Performance Manager of the Year.
Dr. Korenko served as Vice-President of Westinghouse Hanford, Executive Vice President of Closure at Rocky Flats and Chief Operating Officer for Curtiss-Wright Electro-Mechanical
Division producer of the nuclear components for all the United States submarines and aircraft carriers and for commercial nuclear power reactors.
He is currently CEO and President of Vivos Inc. developing Yttrium-90 brachytherapy for animals and humans.
Michael Pollack
Chief Financial Officer
Michael Pollack, CPA is the Partner-in-Charge of KBL’s audit quality and control, and the Partner-in-Charge of KBL’s Public Company (SEC) Practices Group. He has over 20 years of
experience in public accounting and consulting to both publicly traded and privately held companies. He also has vast knowledge of capital financing, debt refinancing, strategic
repositioning, development restructuring, and private placement offerings.
Michael’s specialties include reverse merger transactions and registration processes for the Securities and Exchange Commission. Prior to joining KBL Michael had been a director in
regional firms specializing in the development and growth of their SEC practice. He has directed various SEC engagements as well as financial service engagements as an auditor, and
has been utilized as an outsourced CFO for a number of public companies all performed in accordance with the standards established by the Public Company Accounting Oversight Board. He
has prepared numerous market and financial feasibility studies that have directly led to the raising of several billion of dollars in financing.
Michael graduated from the University of Maryland with a Bachelors of Arts in Economics. Michael is a member of the American Institute of Certified Public Accountants, as well as
licensed to practice in New Jersey, Pennsylvania, New York and Maryland.
David J. Swanberg
Chief Technical Manager
Mr. Swanberg has over 30 years’ experience in Radiochemical Processing, Medical Isotope Production, Nuclear Waste Management, Materials Science, Regulatory Affairs, and Project
Management. He has worked in diverse organizations ranging from small start-up businesses to corporations with multi-billion dollar annual revenues.
He previously served as Executive Vice President of Operations for IsoRay Medical Inc. managing day-to-day operations, R&D, and New Product Development. Mr. Swanberg was a
co-founder of IsoRay and led the initial Cs-131 brachytherapy seed product development, FDA 510(k) submission/clearance, and NRC Sealed Source review and registration. He led the
radiation dosimetry evaluations to meet American Association of Physicists in Medicine guidelines and is a current member of the AAPM.
Mr. Swanberg served on the IsoRay Board of Directors and participated in several capital financing rounds totalling over $30M. He holds a BA in Chemistry from Bethel University (MN)
and an MS in Chemical Engineering from Montana State University. He has numerous technical publications and holds several patents.
Dr. Donald A. Ludwig
Special Projects
Donald A. Ludwig, PhD., is Director of Special Projects for Vivos Inc. As an expert in particle accelerator applications in radiation therapy, nuclear medicine and radioisotope
production.
Dr. Ludwig also serves as an advisor to numerous entities in the field, both domestic and foreign. Among these are the Atomic Energy of Canada, the U. S. Department of Energy Labs at
Los Alamos, Berkeley, Fermi, Hanford and Oak Ridge, the Israel Atomic Energy Agency, the Australian Nuclear Science and Technology Organization, the Budker Institute of Nuclear
Physics in Novosibirsk, Siberia, the Malaysian Institute of Nuclear Technology and the Bhabha Atomic Research Center in Mumbai, India.
He holds advanced degrees in nuclear physics, medical physics and marketing from top tier Universities. Dr. Ludwig’s endeavors for Vivos Inc. are focused on facilitating the return of
clinical radioisotope production to the US.
Dr. Nigel R. Stevenson
Chief Science Officer
Dr. Stevenson is Vivos's Chief Science Officer. He brings with him an impressive background in isotope production. He began his career as a research scientist at TRIUMF, the Canadian
Accelerator Facility, before heading up the Isotope Production and Applied Technology group at TRIUMF responsible for the production of a wide variety of radioactive medical isotopes
for Nordion in addition to specialized isotope production technology.
In 1999 he became the V.P. of Isotope Production and Research for Theragenics Corporation in Atlanta, GA. In this role he was responsible for installing and operating the world’s
largest cyclotron facility (14 machines) used to produce radiochemicals for pharmaceuticals and medical devices.
He also had technical oversight of a large scale stable isotope separation facility in Oak Ridge, TN. He was appointed the Chief Operating Officer of Trace Life Sciences, before
assuming his current role as Chief Operating Officer of Clear Vascular.
Additionally, he is the CEO of TcNet, LLC, a company that is investigating the use of PET cyclotron systems to produce a number of additional radiochemicals. Dr. Stevenson obtained
his Ph.D. at the University Of London, UK in 1983 in Nuclear Physics.
Home Page Cover Image:
Veterinarian Dr. Michelle Myer from Vista Veterinarian Hospital in Kennewick, WA.
Seen here administering IsoPet® therapy to a feline suffering from a sarcoma.
RadioGel™ is a hydrogel liquid containing tiny yttrium-90 phosphate particles that may be administered directly into a tumor. The hydrogel is an yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
IsoPet® Therapy Application(s)
Precision Radionuclide Therapy (PRnT)
Vivos Inc. - (OTCQB:RDGL) Investor Relations
Contact
| bg-primary | |
| bg-primary-light | |
| bg-primary-dark | |
| bg-secondary | |
| bg-secondary-dark |
| body | |
| top-header | |
| header | |
| content |
| background | |
| text color | |
| link color | |
| horizontal line |
| style 1 | |
| style 2 | |
| style 3 |
| social icons | |
| navigation color | |
| subnav background |
| background color | |
| navigation color |
Note: All changes made here will be applied to your entire website.
